These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 8757297)

  • 21. Pathways of antigen processing and presentation.
    Watts C; Powis S
    Rev Immunogenet; 1999; 1(1):60-74. PubMed ID: 11256573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of MHC class I-restricted antigen processing and cross-presentation.
    Cresswell P; Ackerman AL; Giodini A; Peaper DR; Wearsch PA
    Immunol Rev; 2005 Oct; 207():145-57. PubMed ID: 16181333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.
    Schubert U; Antón LC; Gibbs J; Norbury CC; Yewdell JW; Bennink JR
    Nature; 2000 Apr; 404(6779):770-4. PubMed ID: 10783891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products.
    Qian SB; Reits E; Neefjes J; Deslich JM; Bennink JR; Yewdell JW
    J Immunol; 2006 Jul; 177(1):227-33. PubMed ID: 16785518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-presentation: underlying mechanisms and role in immune surveillance.
    Rock KL; Shen L
    Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights from MHC-bound peptides.
    Margalit H; Altuvia Y
    Novartis Found Symp; 2003; 254():77-90; discussion 91-101, 216-22, 250-2. PubMed ID: 14712933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-presentation in viral immunity and self-tolerance.
    Heath WR; Carbone FR
    Nat Rev Immunol; 2001 Nov; 1(2):126-34. PubMed ID: 11905820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide.
    Cascio P; Hilton C; Kisselev AF; Rock KL; Goldberg AL
    EMBO J; 2001 May; 20(10):2357-66. PubMed ID: 11350924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands.
    Dolan BP; Bennink JR; Yewdell JW
    Cell Mol Life Sci; 2011 May; 68(9):1481-9. PubMed ID: 21416150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway.
    Shastri N; Cardinaud S; Schwab SR; Serwold T; Kunisawa J
    Immunol Rev; 2005 Oct; 207():31-41. PubMed ID: 16181325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral interference with MHC class I antigen presentation pathway: the battle continues.
    Ambagala AP; Solheim JC; Srikumaran S
    Vet Immunol Immunopathol; 2005 Aug; 107(1-2):1-15. PubMed ID: 15978672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rigidification of the alpha2 helix of an MHC class I molecule by a valine to proline mutation in position 165 does not prevent peptide-specific antigen presentation.
    Plaksin D; Polakova K; Mage MG; Margulies DH
    J Immunol; 1997 Nov; 159(9):4408-14. PubMed ID: 9379039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MHC class I-associated presentation of exogenous peptides is not only enhanced but also prolonged by linking with a C-terminal Lys-Asp-Glu-Leu endoplasmic reticulum retrieval signal.
    Wang L; Wu YZ; Chen A; Zhang JB; Yang Z; Niu W; Geng M; Ni B; Zhou W; Zou LY; Jiang M
    Eur J Immunol; 2004 Dec; 34(12):3582-94. PubMed ID: 15495159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoribosomes: Where's there's fire, there's fire.
    Wei J; Yewdell JW
    Mol Immunol; 2019 Sep; 113():38-42. PubMed ID: 29361306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flu DRiPs in MHC Class I Immunosurveillance.
    Wei J; Yewdell JW
    Virol Sin; 2019 Apr; 34(2):162-167. PubMed ID: 30456657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis?
    Dolan BP; Knowlton JJ; David A; Bennink JR; Yewdell JW
    J Immunol; 2010 Dec; 185(11):6728-33. PubMed ID: 21048111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the Deubiquitinase Usp14 Diminishes Direct MHC Class I Antigen Presentation.
    Palmer AL; de Jong A; Leestemaker Y; Geurink PP; Wijdeven RH; Ovaa H; Dolan BP
    J Immunol; 2018 Feb; 200(3):928-936. PubMed ID: 29282303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Interferons on Presentation of Defective Ribosomal Products as HLA Peptides.
    Komov L; Melamed Kadosh D; Barnea E; Admon A
    Mol Cell Proteomics; 2021; 20():100105. PubMed ID: 34087483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Premature translational termination products are rapidly degraded substrates for MHC class I presentation.
    Lacsina JR; Marks OA; Liu X; Reid DW; Jagannathan S; Nicchitta CV
    PLoS One; 2012; 7(12):e51968. PubMed ID: 23251665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules.
    Yewdell JW; Schubert U; Bennink JR
    J Cell Sci; 2001 Mar; 114(Pt 5):845-51. PubMed ID: 11181168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.